Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
9-ING-41 in Patients With Advanced Cancers
Complete Title: Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors
Trial Phase: I/II
Investigator: Andrew Coveler
GSK-3ß is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3ß inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
Keywords:
- Bladder Cancer
- Breast Cancer
- Pancreatic Cancer
- Sarcoma
- Glioblastoma
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I/II
Andrew Coveler
RG1006626
NCT03678883
Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors
Bladder Cancer
Breast Cancer
Pancreatic Cancer
Sarcoma
Glioblastoma